Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
BPM 31510, a clinical stage metabolic modulator, demonstrates therapeutic efficacy in glioblastoma models of temozolomide chemosensitive and resistance by targeting mitochondrial function Dadali, T., Kulkarni, S., Ng, R., Awate, P., Mogre, S., Diers, A. R., Jang, T., Merchant, M., Sun, J., Gesta, S., Thapa, K., Nagpal, S., Recht, L., Narain, N. R., Sarangarajan, R. AMER ASSOC CANCER RESEARCH. 2018
View details for DOI 10.1158/1538-7445.AM2018-873
View details for Web of Science ID 000468818902374